Have a personal or library account? Click to login
Mobilization with cyclophosphamide reduces the number of lymphocyte subpopulations in the leukapheresis product and delays their reconstitution after autologous hematopoietic stem cell transplantation in patients with multiple myeloma Cover

Mobilization with cyclophosphamide reduces the number of lymphocyte subpopulations in the leukapheresis product and delays their reconstitution after autologous hematopoietic stem cell transplantation in patients with multiple myeloma

Open Access
|May 2016

Figures & Tables

The mean lymphocyte, natural killer (NK) cell and Treg cell counts (109/L) before mobilization and on collection day with 95 % confidence interval (CI) for mobilization with cyclophosphamide (cyclo), pegfilgras tim (pegG-CSF) and filgrastim (G-CSF).
The mean lymphocyte, natural killer (NK) cell and Treg cell counts (109/L) before mobilization and on collection day with 95 % confidence interval (CI) for mobilization with cyclophosphamide (cyclo), pegfilgras tim (pegG-CSF) and filgrastim (G-CSF).

Mean lymphocyte (Lym), natural killer (NK) and T regulatory (Treg) cell counts with 95 % confidence interval (CI) before mobilization, on collection day, in the leukapheresis product and on day 15 after autologous hematopoietic stem cell transplantation (D+15) for mobilization regimens using cyclophophamide, filgrastim (G-CSF) and pegfilgrastim

Time pointCollection regimenCyclophosphamidePegfilgrastimG-CSF
Mean value95% CIMean value95% CIMean value95% CISig
Before mobilizationLym (× 109/L)1.811.27–2.341.481.17–1.801.431.20–1.66
NK (× 109/L)0.200.15–0.260.180.12–0.230.220.15–0.28
Treg (× 106/L)8.534.1–12.9105.28–14.66.864.24–9.48
Collection dayLym (× 109/L)1.080.52–1.6432.46–3.543.082.65–3.51< .001
NK (× 109/L)0.070.01–0.130.420.3–0.540.520.43–0.62< .001
Treg (× 106/L)14.43.73–25.120.412.4–28.518.510.6–26.4.646
Leukapheresis productLym(× 109/L)50.136–64.211296.6–12911294.7–130< .001
NK (× 109/L)4.180.72–7.6414.311.9–16.617.512.7–22.4< .001
Treg (× 106/L)1030392–16701030400–1650714430–9970.531
D+15Lym (× 109/L)0.310.14–0.470.470.38–0.550.470.36–0.590.115
NK (× 109/L)0.050–0.850.100.04–0.160.100–0.340.357
Treg (× 106/L)27.84.45–51.136.60–10120–5.740.691

Patient characteristics

CharacteristicsTotal number of patientsG-CSF mobilizationPegfilgrastim mobilizationCyclophosphamide mobilization
Numbers4820199
Sex, M/F25 / 2311 / 99 / 105 / 4
Median age (Range) years61 (35–71)60 (35–69)64 (51–71)59 (42–63)
ISS stage 1/2/313/17/183/8/97/7/53/2/4
Median cycles of chemotherapy4444
Patients with prior radiotherapy11380
Response VGPR/PR/SD11/9/010/8/13/5/1
Poor mobilizers3120
DOI: https://doi.org/10.1515/raon-2016-0028 | Journal eISSN: 1581-3207 | Journal ISSN: 1318-2099
Language: English
Page range: 402 - 408
Submitted on: Oct 19, 2015
Accepted on: Jan 31, 2016
Published on: May 12, 2016
Published by: Association of Radiology and Oncology
In partnership with: Paradigm Publishing Services
Publication frequency: 4 times per year

© 2016 Matevz Skerget, Barbara Skopec, Darja Zontar, Peter Cernelc, published by Association of Radiology and Oncology
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.